Latrepirdine: Molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Bharadwaj, P R ^a   Bates, K A ^b   Porter, T ^a   Teimouri, E ^a   Perry, G ^c   Steele, J W ^d   Gandy, S ^e   Groth, D ^f   Martins, R N ^a,b,g   Verdile, Giuseppe ^a,b,f,g  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f CURTIN UNIVERSITY   (Australia)

^g HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; Latrepirdine; Mechanism of action

Indexed keywords

ALPHA SYNUCLEIN; DIMEBON; TAR DNA BINDING PROTEIN; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; LYSOSOME; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; ANIMAL; COGNITION; HUNTINGTON CHOREA;

ALZHEIMER DISEASE; ANIMALS; COGNITION; HUMANS; HUNTINGTON DISEASE; INDOLES; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 84890132186     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.97     Document Type: Review

References (86)

1. Omerovic M, Teipel SJ, Hampel T. Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor]. Nervenarzt 2007; 78: 1052-1057. (Pubitemid 47396477)
2. Tariot PN. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. J Clin Psychiatry 2006; 67(Suppl 3): 15-22; quiz 23.
3. Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006; 77: 429-438.
4. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: e338.
5. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939: 425-435. (Pubitemid 32620096)
6. Matveeva IA. Action of dimebon on histamine receptors. Farmakol Toksikol 1983; 46: 27-29. (Pubitemid 13038960)
7. Shadurskii KS, Matveeva IA, Il'iuchenok T. Therapeutic and protective properties of dimebon in burns. Farmakol Toksikol 1983; 46: 90-92. (Pubitemid 13001040)
8. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-215. (Pubitemid 351978110)
9. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010; 67: 154-160.
10. Contact: An Alzheimer's Disease Investigational Trial. Available at: http://www. contactstudy.com/ (accessed on 2010).
11. Horizon: A Huntington Disease Investigational Trial. Available at: http://www. horizontrial.com/index.php (accessed on 2010).
12. Editorial. Mechanism matters. Nat Med 2010; 16: 347.
13. Editorial. Learning from failure. Nat Rev Drug Discov 2010; 9: 499.
14. Bachurin SO, Ustyugov AA, Peters O, Shelkovnikova TA, Buchman VL, Ninkina NN. Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds. Dokl Biochem Biophys 2009; 428: 235-238.
15. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000; 129: 544-546.
16. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 2008; 3: 15.
17. Okun I, Tkachenko SE, Khvat A, Mitkin O, Kazey V, Ivachtchenko AV. From antiallergic to anti-Alzheimer's: molecular pharmacology of Dimebon. Curr Alzheimer Res 2010; 7: 97-112.
18. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 2010; 21: 389-402.
19. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142: 39-51.
20. Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE et al. Dimebon alters hippocampal amyloid pathology in 3-Tg-AD mice. Int J Physiol Pathophysiol Pharmacol 2012; 4: 115-127.
21. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH et al. Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry 2012; 18: 882-888.
22. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry 2012; 18: 889-897.
23. Burns A, Jacoby R. Dimebon in Alzheimer's disease: old drug for new indication. Lancet 2008; 372: 179-180. (Pubitemid 351978088)
24. Galenko-Iaroshevskii PA, Chekanova OA, Skibitskii VV, Bartashevich VV, Khankoeva AI, Poliashova TI. Antiarrhythmic properties of dimebone. Biull Eksp Biol Med 1995; 119: 375-377.
25. Galenko-Iaroshevskii PA, Sheikh-Zade Iu R, Chekanova OA, Melkumova ER, Bartashevich VV, Khankoeva AI. Effect of dimebone on coronary blood flow and myocardial contractibility. Biull Eksp Biol Med 1996; 121: 506-508.
26. Meneses A. Role of 5-HT6 receptors in memory formation. Drug News Perspect 2001; 14: 396-400. (Pubitemid 33140705)
27. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr. FJ, Shen Y et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-1410. (Pubitemid 24100360)
28. Mattson MP. Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2 influx in cultured hippocampal neurons. Neuron 1990; 4: 105-117. (Pubitemid 20149759)
29. Mills LR, Kater SB. Neuron-specific and state-specific differences in calcium homeostasis regulate the generation and degeneration of neuronal architecture. Neuron 1990; 4: 149-163. (Pubitemid 20149763)
30. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PG et al. Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 963-1008. (Pubitemid 29468909)
31. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41: 135-144. (Pubitemid 27062653)
32. Palmer GC, Widzowski D. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids 2000; 19: 151-155.
33. Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003; 136: 474-477. (Pubitemid 39137308)
34. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-672. (Pubitemid 32119421)
35. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993: 334-344, discussion 345-339. (Pubitemid 36808462)
36. Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2) channels. Bull Exp Biol Med 2001; 132: 1079-1083. (Pubitemid 34295938)
37. Schambra UB, Mackensen GB, Stafford-Smith M, Haines DE, Schwinn DA. Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease. Neuroscience 2005; 135: 507-523. (Pubitemid 41317388)
38. Zheng CJ, Han LY, Yap CW, Ji ZL, Cao ZW, Chen YZ. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006; 58: 259-279.
39. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998; 7: 1507-1509. (Pubitemid 28429933)
40. Thome J, Retz W, Baader M, Pesold B, Hu M, Cowen M et al. Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease. J Neural Transm 2001; 108: 1175-1180. (Pubitemid 33022767)
41. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA et al. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009; 78: 1035-1042.
42. Shadurskaia SK, Khomenko AI, Pereverzev VA, Balaklevskii AI. Neuromediator mechanisms of the effect of the antihistamine agent dimebone on the brain. Biull Eksp Biol Med 1986; 101: 700-702. (Pubitemid 16086204)
43. Gankina EM, Porodenko NV, Kondratenko TI, Severin ES, Kaminka ME, Mashkovskii MD. The effect of antihistaminic preparations on the binding of labelled mepyramine, ketanserin and quinuclidinyl benzilate in the rat brain. Eksp Klin Farmakol 1993; 56: 22-24.
44. Hanin I. The AF64A model of cholinergic hypofunction: an update. Life Sci 1996; 58: 1955-1964. (Pubitemid 26160433)
45. Geldenhuys WJ, Darvesh AS, Dluzen DE. Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion. Neurochem Int 2012; 60: 806-808.
46. Vignisse J, Steinbusch HW, Bolkunov A, Nunes J, Santos AI, Grandfils C et al. Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 510-522.
47. Cowley TR, Gonzalez-Reyes RE, Richardson JC, Virley D, Upton N, Lynch MA. The age-related gliosis and accompanying deficit in spatial learning are unaffected by Dimebon. Neurochem Res 2012; 38: 1190-1195.
48. Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry Jr AV, Buccafusco JJ. The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. Br J Pharmacol 2011; 164: 970-978.
49. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 2010; 333: 748-757.
50. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006; 553: 109-119. (Pubitemid 44779592)
51. Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML et al. Latrepirdine (Dimebon) enhances autophagy and reduces intracellular GFPAbeta42 levels in yeast. J Alzheimers Dis 2012; 32: 949-967.
52. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-21570. (Pubitemid 37413154)
53. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M et al. Preclinical study of dimebon on beta-amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 2011; 6: 7.
54. Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG et al. Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 2011; 8: 430-437.
55. De Jesus-Cortes H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 2012; 109: 17010-17015.
56. Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA et al. dimebon slows progression of proteinopathy in gamma-synuclein transgenic mice. Neurotoxicol Res 2012; 22: 33-42.
57. Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2012; 109: 17016-17021.
58. Combarros O, Rodriguez-Rodriguez E, Mateo I, Vazquez-Higuera JL, Infante J, Berciano J et al. APOE dependent-association of PPAR-gamma genetic variants with Alzheimer's disease risk. Neurobiol Aging 2011; 32: 547 e541-546.
59. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M et al. Multitarget- directed ligands to combat neurodegenerative diseases. J Med Chem 2008; 51: 347-372. (Pubitemid 351252260)
60. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32: 486-510. (Pubitemid 40591181)
61. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005; 57: 695-703. (Pubitemid 40628858)
62. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004; 89: 1417-1426. (Pubitemid 38802663)
63. Wang X, Michaelis ML, Michaelis EK. Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. Curr Genomics 2010; 11: 618-633.
64. Naga KK, Geddes JW. Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 2011; 13: 31-36.
65. Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid-beta induced impairments of mitochondrial form and function. J Alzheimers Dis 2012; 31: 21-32.
66. Day M, Chandran P, Luo F, Rustay NR, Markosyan S, LeBlond D et al. Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. Neuroscience 2011; 189: 299-304.
67. Bastianetto S, Krantic S, Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev Med Chem 2008; 8: 429-435.
68. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Ab aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 2009; 13: 412-421.
69. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12: 801-808. (Pubitemid 44050070)
70. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009; 583: 2419-2424.
71. Ustyugov AA, Shelkovnikova TA, Kokhan VS, Khritankova IV, Peters O, Buchman VL et al. Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo. Bull Exp Biol Med 2012; 152: 731-733.
72. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D et al. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 2009; 4: 51.
73. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008; 58: 42-51. (Pubitemid 351467029)
74. Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci 2009; 29: 9704-9713.
75. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717-1721. (Pubitemid 32004796)
76. Ivachtchenko AV, Frolov EB, Mitkin OD, Tkachenko SE, Okun IM, Khvat AV. Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles. Bioorg Med Chem Lett 2010; 20: 78-82.
77. Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 2000; 60: 121-132. (Pubitemid 30625015)
78. Du W, Aloyo VJ, Harvey JA. Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. Brain Res 1997; 770: 26-29. (Pubitemid 27468046)
79. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. Beta-carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 2010; 48: 839-845.
80. Yang YJ, Lee JJ, Jin CM, Lim SC, Lee MK. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol 2008; 587: 57-64.
81. Pimpinella G, Palmery M. Interaction of beta-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett 1995; 189: 121-124.
82. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 2009; 276: 6324-6337.
83. Pfizer and Medivation Announce Results from Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer's Disease Development Program. Available at: http://investors. medivation.com/releasedetail.cfm?ReleaseID=448818 (accessed on 2010).
84. Concert: An Alzheimer's Disease Investigational Trial. Available at: http:// concertstudy.com/index.html (accessed on 2010).
85. Constellation: An Alzheimer's disease Research Study. Available at: http:// www.constellationstudy.com/index.php (accessed on 2010).
86. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebocontrolled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub 2012; 24: 159-166.